Treatment of recalcitrant psoriasis with daclizumab [19]

British Journal of Dermatology

Volumn 144, Issue 1, 2001, Pages 209-210

  Wohlrab, J ^a   Fischer, M ^a   Taube, K M ^a   Marsch, W C ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN;

ADULT; CASE REPORT; DRUG MECHANISM; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LETTER; LIVER TOXICITY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PSORIASIS; PUVA; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PSORIASIS;

EID: 0035128791     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.03991.x     Document Type: Letter

References (5)

1. Guidelines for measurement of skin colour and erythema
2. The pathogenesis of psoriasis: Immunological facts and speculations
3. Pathogenesis of psoriasis
4. Reduction of acute renal allograft rejection by daclizumab
5. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial